NEW YORK--(BUSINESS WIRE)--Research supporting a new effective use of Johnson & Johnson’s (JNJ) drug Xarelto could be incrementally positive for the company from an operational and cash generation standpoint, if approved by the FDA, as the already marketed drug could open the door to a new batch of customers.
